Auris Medical Holding Ltd. announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform, based on outcomes from studies with OligoPhore™ enabled KRAS silencing, and a well-defined regulatory and development pathway.
[Auris Medical Holding Ltd.]
7992332
{7992332:nan}
apa
50
1
164259
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
